B7-H2/ICOSLG Antibody (136716)

In the presence of Human CD3 epsilon Monoclonal Antibody (20 ng/mL, Catalog # MAB100), Recombinant Human B7‑H2 Fc Chimera (Catalog # 165-B7) stimulates proliferation in PHA-activated human T cells in a dose-dependent manner (orange line). Under these conditions, proliferation elicited by Rec­ombinant Human B7‑H2 Fc Chimera (3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human B7‑H2 Monoclonal Antibody (Catalog # MAB1651). The ND50 is typically 1-4 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clone: 136716
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

B7-H2/ICOSLG Antibody (136716) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human B7-H2
  Asp19-Ser258
  Accession # O75144
• Specificity: Detects human B7-H2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) B7-1, rhB7-2, rhB7-H1, rhB7-H3, recombinant mouse (rm) B7-H2, or rmPD-L2 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: ICOSLG
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 1-4 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-H2/ICOSLG Antibody (136716)

• B7H2
• B7-H2
• B7H2B7 homolog 2
• B7-H2B7-related protein 1
• B7RP-1
• B7RP1B7-like protein Gl50
• B7RP-1LICOS
• CD275 antigen
• CD275
• GL50
• GL50transmembrane protein B7-H2 ICOS ligand
• ICOSL
• ICOS-L
• ICOSLG
• inducible T-cell co-stimulator ligand
• KIAA0653ICOS ligand

Background

Human B7-H2, also called B7RP-1, B7h, LICOS, and GL50, is a 60 kDa member of the B7 family of immune costimulatory proteins, which includes B7-1, B7-2, B7-H1 (PD-L1), PD-L2, and B7-H3. B7 proteins are members of the immunoglobulin (Ig) superfamily; the extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. Family members share about 20‑25% amino acid identity. Within the extracellular domain, human B7-H2 shares 49% and 54% amino acid sequence identity with mouse and rat B7-H2, respectively. B7-H2 has been identified as the ligand for ICOS, a member of the CD28 family of costimulatory receptors. Human B7-H2 is a 309 amino acid (aa) protein with a putative 18 aa signal peptide, a 239 aa extracellular domain, an 18 aa transmembrane region, and a 33 aa cytoplasmic domain. Human B7-H2 is expressed constitutively on resting B cells, dendritic cells, and at low levels on monocytes. The B7-H2/ICOS interaction appears to play roles in T cell dependent B cell activation and T_h differentiation.

1. Coyle, A.J. and J.C. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
2. Ling, V. et al. (2000) J. Immunol. 164:1653.
3. Wang, S. et al. (2000) Blood 96:2808.
4. Brodie, D. et al. (2000) Curr. Biol. 10:333.
5. Mages, H.W. et al. (2000) Eur. J. Immunol. 30:1040.
6. Swallow, M.M. et al. (1999) Immunity 11:423.
7. Yoshinaga, S.K. et al. (1999) Nature 402:827.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: ICOSLG
• Uniprot:
  • O75144()